Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-16T15:15:59.378Z Has data issue: false hasContentIssue false
  • English
  • Français

Stimulants in Bipolar Disorder: Beyond Common Beliefs

Published online by Cambridge University Press:  07 November 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters
Information
CNS Spectrums , Volume 15 , Issue 7 , July 2010 , pp. 469 - 470
Copyright
Copyright © Cambridge University Press 2010

References

1.McIntyre, R. Bipolar disorder and ADHD: clinical concerns. CNS Spectr. 2009; 14(7 Suppl 6): 8–9.CrossRefGoogle ScholarPubMed
2.Hegerl, U, Olbrich, S, Schoenknecht, P, Sander, C. [Manic behavior as an autoregulatory attempt to stabilize vigilance]. Nervenarzt. 2008; 79(11): 1283–1290.CrossRefGoogle ScholarPubMed
3.Hegerl, U, Sander, C, Olbrich, S, Schoenknecht, P. Are psychostimulants a treatment option in mania? Pharmacopsychiatry. 2009; 42(5): 169–174.CrossRefGoogle ScholarPubMed
4.Hegerl, U, Himmerich, H, Engmann, B, Hensch, T. Mania and attention-deficit/hyperactivity disorder: common symptomatology, common pathophysiology and common treatment? Curr Opin Psychiatry. 2010; 23(1): 1–7.CrossRefGoogle ScholarPubMed
5.Schoenknecht, P, Olbrich, S, Sander, C, Spindler, P, Hegerl, U. Treatment of acute mania with modafinil monotherapy. Biol Psychiatry. 2010; 67(11): e55–e57.CrossRefGoogle ScholarPubMed
6.Bschor, T, Müller-Oerlinghausen, B, Ulrich, G. Decreased level of EEG-vigilance in acute mania as a possible predictor for a rapid effect of methylphenidate: a case study. Clin Electroencephal. 2001; 32(1): 36–39.CrossRefGoogle ScholarPubMed
7.Hensch, T, Himmerich, H, Hegerl, U. Attention deficit hyperactivity disorder and bipolar disorder: common causes common cure? J Atten Disord. In press.Google Scholar
8.Gelperin, K, Phelan, K. Psychiatric adverse events associated with drug treatment of ADHD: review of postmarketing safety data. FDA Report PID D050243. US Food and Drug Administration, March 3, 2006. Available at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_11_01_AdverseEvents.pdf. Accessed June 2010.Google Scholar
9.Mosholder, A. Psychiatric adverse events in clinical trials of drugs for ADHD. FDA Report PID D060163. US Food and Drug Administration, March 3, 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_10_01_Mosholder.pdf. 3-3-2006. Accessed June 2010.Google Scholar
10.Phelan, K. Summary of psychiatric and neurological adverse events from June 2005 1-year post pediatric exclusivity reviews of Concerta and other methylphenidate products. US Food and Drug Administration, 2006. Available at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_09_01_Methsummary.pdf. Accessed June 2010.Google Scholar
11.Phelan, K. One year post-pediatric exclusivity postmarketing adverse event review: Adderall XR. FDA Report PID D040761. US Food and Drug Administration, Jan 5, 2006. Available at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_05_02_AdderallSafetyReview.pdf. Accessed June 2010.Google Scholar
12.Ross, RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006; 163(7): 1149–1152.Google Scholar
13.Reimherr, FW, Williams, ED, Strong, RE, Mestas, R, Soni, P, Marchant, BK. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 20071; 68(1): 93–101.CrossRefGoogle Scholar
14.Galanter, CA, Carlson, GA, Jensen, PS, et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J Child Adolesc Psychopharmacol. 2003; 13(2): 123–136.CrossRefGoogle ScholarPubMed
15.Waxmonsky, J, Pelham, WE, Gnagy, E, et al. The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. J Child Adolesc Psychopharmacol. 2008; 18(6): 573–588.Google Scholar
16.Kowatch, RA, Sethuraman, G, Hume, JH, Kromelis, M, Weinberg, WA. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry. 2003; 53(11): 978–984.CrossRefGoogle ScholarPubMed
17.Kummer, A, Teixeira, A. Methylphenidate in attention deficit hyperactivity disorder and bipolar disorder. Australas Psychiatry. 2008; 16(6): 458–459.Google Scholar
18.Scheffer, RE, Kowatch, RA, Carmody, T, Rush, AJ. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2005; 162(1): 58–64.CrossRefGoogle ScholarPubMed
19.Findling, RL, Short, EJ, McNamara, NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(11): 1445–1453.CrossRefGoogle ScholarPubMed
20.Zeni, CP, Tramontina, S, Ketzer, CR, Pheula, GF, Rohde, LA. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol. 2009; 19(5): 553–561.CrossRefGoogle ScholarPubMed
21.Carlson, PJ, Merlock, MC, Suppes, T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004; 6(5): 416–420.CrossRefGoogle ScholarPubMed
22.El-Mallakh, RS. An open study of methylphenidate in bipolar depression. Bipolar Disord. 2000; 2(1): 56–59.Google Scholar
23.Fernandes, PP, Petty, F. Modafinil for remitted bipolar depression with hypersomnia. Ann Pharmacother. 2003; 37(12): 1807–1809.CrossRefGoogle ScholarPubMed
24.Lydon, E, El-Mallakh, RS. Naturalistic long-term use of methylphenidate in bipolar disorder. J Clin Psychopharmacol. 2006; 26(5): 516–518.Google Scholar
25.Nasr, S, Wendt, B, Steiner, K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord. 2006; 95(1–3): 111–114.Google Scholar
26.Frye, MA, Grunze, H, Suppes, T et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007; 164(8): 1242–1249.Google Scholar
27.Plante, DT. Treatment-emergent hypomania or mania with modafinil. Am J Psychiatry. 2008; 165(1): 134–135.CrossRefGoogle ScholarPubMed
28.Plante, DT, Winkelman, JW. Sleep disturbance in bipolar disorder: therapeutic implications. Am J Psychiatry. 2008; 165(7): 830–843.Google Scholar
29.Sobanski, E, Schredl, M, Kettler, N, Alm, B. Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep. 2008; 31(3): 375–381.Google Scholar